Wilson N, Silverman M
Br Med J (Clin Res Ed). 1982 Mar 20;284(6319):863-6. doi: 10.1136/bmj.284.6319.863.
Slow-release aminophylline, although widely used for the prophylaxis of childhood asthma, has had only limited formal assessment. A four-month double-blind cross-over trial of slow-release aminophylline (14 mg/kg twice daily) was carried out in 24 children with perennial asthma. Satisfactory serum theophylline concentrations were obtained in 17 children, with few side effects. There was a significant improvement in mild daytime and night-time symptoms. The incidence of more severe symptoms was unaffected. Treatment did not improve the mean peak expiratory flow or reduce the incidence of use of bronchodilators. It is concluded that slow-release aminophylline has a place in the prophylaxis of perennial childhood asthma but is unsuitable for children who suffer from severe attacks. The cross-over trial design has severe limitations.
缓释氨茶碱虽然广泛用于儿童哮喘的预防,但仅有有限的正式评估。对24名常年性哮喘儿童进行了一项为期四个月的缓释氨茶碱(每日两次,每次14毫克/千克)双盲交叉试验。17名儿童获得了满意的血清茶碱浓度,且副作用很少。轻度白天和夜间症状有显著改善。更严重症状的发生率未受影响。治疗并未改善平均呼气峰值流速,也未降低支气管扩张剂的使用发生率。结论是,缓释氨茶碱在儿童常年性哮喘的预防中有一席之地,但不适用于严重发作的儿童。交叉试验设计有严重局限性。